@Contruction@rigger@scafolder@operation
Budget: $15 – $25 USD
@Operator cren, @operator excavator, @operator operator, @skills scafolding, @skills rigger
TARGETED (Targeted operating excavator)
TARGETED (Targeted operating cren)
$250.000 USD
File
Targeted Genome Editor Delivery (TARGETED) Challenge - Phase 2
Revolutionizing technology development of delivery systems for in vivo genome editing.
A $6,000,000 competition to improve in vivo delivery technologies for genome editors in two Target Areas: 1. Programmable delivery systems, and 2. Non-viral delivery across the blood-brain barrier.
You need to fill out the Registration Form and be registered on the Freelancer.com platform before submitting the solution.
Subject of the Challenge
Recent advancements in the genome editing technology field have enabled scientists to manipulate genomic sequences rapidly and efficiently. Despite revolutionary progress in this area, several challenges remain. Existing gene editing technologies like CRISPR-cas9, base editors and prime editors have great potential, but existing delivery technologies are not able to deliver gene editing technologies to many target tissues and cell types in sufficient quantities, which hinders clinical applications. While some cell types, like hepatocytes in the liver, have many delivery technologies capable of delivering genome editors, there are many other organs and cell types that are harder to reach.
The Targeted Genome Editor Delivery (TARGETED) Challenge is a $6,000,000 challenge to improve the current state of in-vivo delivery technologies for genome editors in two Target Areas: 1. Programmable Delivery System for Gene Editing, and 2. Crossing the Blood-Brain Barrier.
The National Institutes of Health (NIH), through the Common Fund’s Somatic Cell Genome Editing (SCGE) program, is seeking Participants with ideas or early-stage solutions to join the Challenge with the chance to win up to $1,000,000 and have their solution independently tested and validated in large animal models through NIH-supported independent evaluation relevant to preclinical assessments of investigational products.
Phase 2
In Phase 2, Participants must submit data from studies that demonstrate delivery and editing performance as well as describe their methodology, technology, and how their solution addresses the Challenge criteria. Participation in Phase 1 is not a requirement for participation in Phase 2; however, it is strongly encouraged. Up to 10 winners of Phase 2 will be each awarded $250,000 and will be eligible to compete in Phase 3.
Only Phase 2 winners will be eligible to participate in Phase 3.
Phase 3
Phase 3 is separated into Phase 3a and 3b; all Participants must submit solutions for Phase 3a to be eligible to participate in Phase 3b.
For Phase 3a, Participants must submit all required information showing that their technology is ready for large animal testing through NIH-supported independent evaluation andhas the ability to solve the requirements for one of the Target Areas.
Up to 6 Participants will each be awarded $50,000 and will then prepare for reagent scale up and protocol development for NIH-supported large animal testing.
Participants who submit their reagents and protocols by the deadline for Phase 3b will have access to NIH-funded independent large animal testing to validate their solution. NIH will review the results and only award prizes to Participants whose solutions meet or exceed the criteria.
The top successful solution in each Target Area will be awarded $625,000; the second place solution in each Target Area will be awarded $225,000; the third place solution in each Target Area will be publicly recognized and given an honorable mention award. Participants who participate successfully in all three phases could be awarded up to $1,000,000 in each Target Area.
TARGETED (Targeted operating excavator)
TARGETED (Targeted operating cren)
$250.000 USD
File
Targeted Genome Editor Delivery (TARGETED) Challenge - Phase 2
Revolutionizing technology development of delivery systems for in vivo genome editing.
A $6,000,000 competition to improve in vivo delivery technologies for genome editors in two Target Areas: 1. Programmable delivery systems, and 2. Non-viral delivery across the blood-brain barrier.
You need to fill out the Registration Form and be registered on the Freelancer.com platform before submitting the solution.
Subject of the Challenge
Recent advancements in the genome editing technology field have enabled scientists to manipulate genomic sequences rapidly and efficiently. Despite revolutionary progress in this area, several challenges remain. Existing gene editing technologies like CRISPR-cas9, base editors and prime editors have great potential, but existing delivery technologies are not able to deliver gene editing technologies to many target tissues and cell types in sufficient quantities, which hinders clinical applications. While some cell types, like hepatocytes in the liver, have many delivery technologies capable of delivering genome editors, there are many other organs and cell types that are harder to reach.
The Targeted Genome Editor Delivery (TARGETED) Challenge is a $6,000,000 challenge to improve the current state of in-vivo delivery technologies for genome editors in two Target Areas: 1. Programmable Delivery System for Gene Editing, and 2. Crossing the Blood-Brain Barrier.
The National Institutes of Health (NIH), through the Common Fund’s Somatic Cell Genome Editing (SCGE) program, is seeking Participants with ideas or early-stage solutions to join the Challenge with the chance to win up to $1,000,000 and have their solution independently tested and validated in large animal models through NIH-supported independent evaluation relevant to preclinical assessments of investigational products.
Phase 2
In Phase 2, Participants must submit data from studies that demonstrate delivery and editing performance as well as describe their methodology, technology, and how their solution addresses the Challenge criteria. Participation in Phase 1 is not a requirement for participation in Phase 2; however, it is strongly encouraged. Up to 10 winners of Phase 2 will be each awarded $250,000 and will be eligible to compete in Phase 3.
Only Phase 2 winners will be eligible to participate in Phase 3.
Phase 3
Phase 3 is separated into Phase 3a and 3b; all Participants must submit solutions for Phase 3a to be eligible to participate in Phase 3b.
For Phase 3a, Participants must submit all required information showing that their technology is ready for large animal testing through NIH-supported independent evaluation andhas the ability to solve the requirements for one of the Target Areas.
Up to 6 Participants will each be awarded $50,000 and will then prepare for reagent scale up and protocol development for NIH-supported large animal testing.
Participants who submit their reagents and protocols by the deadline for Phase 3b will have access to NIH-funded independent large animal testing to validate their solution. NIH will review the results and only award prizes to Participants whose solutions meet or exceed the criteria.
The top successful solution in each Target Area will be awarded $625,000; the second place solution in each Target Area will be awarded $225,000; the third place solution in each Target Area will be publicly recognized and given an honorable mention award. Participants who participate successfully in all three phases could be awarded up to $1,000,000 in each Target Area.